Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:SRRA

Sierra Oncology (SRRA) Stock Price, News & Analysis

Sierra Oncology logo

About Sierra Oncology Stock (NASDAQ:SRRA)

Key Stats

Today's Range
$54.99
$54.99
50-Day Range
$54.73
$54.99
52-Week Range
$14.91
$55.19
Volume
N/A
Average Volume
931,731 shs
Market Capitalization
$1.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.

Receive SRRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sierra Oncology and its competitors with MarketBeat's FREE daily newsletter.

SRRA Stock News Headlines

Sierra Oncology Inc.
Download Our Tesla Ebook For Free
Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.
Sierra Coupon for October
See More Headlines

SRRA Stock Analysis - Frequently Asked Questions

Sierra Oncology, Inc. (NASDAQ:SRRA) released its earnings results on Friday, November, 5th. The biotechnology company reported ($2.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.78) by $0.32.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sierra Oncology investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), T2 Biosystems (TTOO), OPKO Health (OPK), Tonix Pharmaceuticals (TNXP), Trevena (TRVN) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
11/05/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SRRA
Previous Symbol
NASDAQ:DNAI
Fax
N/A
Employees
109
Year Founded
N/A

Profitability

Net Income
$-94,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$300,000.00
Book Value
$6.16 per share

Miscellaneous

Free Float
13,650,000
Market Cap
$1.34 billion
Optionable
Optionable
Beta
0.03

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:SRRA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners